KJ BIOSCIENCES, LLC

Biotech · Private

Synthetic Vi polysaccharide conjugate vaccines produced via O-acetylation of plant-derived polygalacturonic acid

Grants
$874K
3 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
8
3 granted · 5 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · A novel broad-spectrum influenza vaccine$290,634
Federal grantDepartment of Health and Human Services · Phase I · Development of a low molecular weight synthetic Vi conjugate vaccine for salmonella typhi$286,507
Federal grantDepartment of Health and Human Services · Phase I · Development of a low molecular weight synthetic Vi conjugate vaccine for salmonella typhi$296,436
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1438UCB S.A.—$788K
1439SIWA Biotech Corp.—$8.7M
1440ARTBIO——
1441KJ BIOSCIENCES, LLC——
1442Centaurus Therapeutics, Inc.—$2.0M
1443ACUREX THERAPEUTICS CORPORATION——
1444Werewolf Therapeutics, Inc.—$104M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 3 granted of 8

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.